A biotech company just asked its shareholders to blow up their own equity by 951% so management can hoard an illiquid crypto token instead of funding the drugs the company was literally built to develop.
Enlivex Therapeutics is the company. The ask is real. The vote is coming within 60 days.
Here's the structure: Enlivex has pledged to hold a shareholder vote within that 60-day window, with a second $400 million tranche remaining entirely optional. That optionality sounds flexible. It isn't. The first move alone represents a near-total destruction of existing shareholder value through a 951% dilution event, which means current holders would be sliced down to a fraction of their stake while management pivots from drug development to crypto accumulation.
This Is the MicroStrategy Playbook, Except Worse
Michael Saylor converted MicroStrategy's software business into a Bitcoin treasury vehicle. That at least had logic: Bitcoin is the most liquid, most recognized crypto asset on the planet. Enlivex isn't talking about Bitcoin. The token in question is described as illiquid, meaning there's no guarantee shareholders could exit the position without cratering its price. Saylor's bet was aggressive. This one is a different animal entirely.
Biotech companies run on capital. Drug trials are expensive, slow, and brutally competitive. Shareholders who backed Enlivex were betting on a pipeline, not a crypto treasury experiment with a token that can't be easily sold. The disconnect between what shareholders signed up for and what management is now proposing is almost impossible to overstate.
Why This Matters Beyond One Small Biotech
This is the trend that should be making institutional crypto watchers nervous and excited at the same time. Nervous because corporate crypto treasury strategies are now spreading far beyond companies with any credible connection to blockchain technology. Excited because even illiquid, obscure tokens are now showing up on corporate balance sheets, which signals just how far the crypto treasury thesis has penetrated boardroom thinking since Strategy's Bitcoin playbook went mainstream.
The risk here is regulatory and reputational. The SEC has already signaled interest in companies that use crypto pivots as stock promotion vehicles. A 951% dilution tied to an illiquid token purchase has the fingerprints of exactly the kind of structure regulators love to make an example of.
What To Watch
The shareholder vote is the trigger. If it passes, watch for copycat moves from other small-cap biotech and pharma companies sitting on stagnant pipelines. If it fails, it becomes the case study that slows the entire micro-cap crypto treasury wave.
Hold the date. This vote lands within 60 days.